Climb Bio, Inc.
Climb Bio, Inc. (CLYM) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · CLYM · as of Jun 9, 2026
Activity summary
Buy transactions
3
P-Purchase only
Sell transactions
4
12 Months
Buy/Sell ratio
0.75
Buy/Sell (by trades)
Overall sentiment
Climb Bio, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
CLYM insider buying and selling by quarter
CLYM insider selling · CLYM insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · CLYM ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
CLYM executive sell shares · CLYM board member insider trading · CLYM insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Feb 25, 2026 | Thomas Stephen Basil Director | Sale | 33,687 | $236K | Form 4 |
| Feb 26, 2026 | Thomas Stephen Basil Director | Sale | 16,313 | $114K | Form 4 |
| Feb 12, 2026 | Thomas Stephen Basil Director | Sale | 90,000 | $471K | Form 4 |
| Feb 13, 2026 | Thomas Stephen Basil Director | Sale | 10,000 | $58K | Form 4 |
| Jan 5, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | 7,111 | $25K | Form 4 |
| Dec 12, 2025 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | 101,462 | $290K | Form 4 |
| Dec 11, 2025 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | 213,099 | $465K | Form 4 |
| Dec 11, 2025 | RA CAPITAL MANAGEMENT, L.P. Director | Other | 20,440,000 | — | Form 4 |
| Aug 7, 2025 | Thomas Stephen Basil Director | Award | 100,375 | — | Form 4 |
| Jun 27, 2025 | Brennan Aoife President and CEO · Director | Option | 68,750 | — | Form 4 |
| Jun 30, 2025 | Brennan Aoife President and CEO · Director | Sale | 20,618 | $25K | Form 4 |
| Jun 27, 2025 | Thomas Stephen Basil Director | Option | 25,094 | — | Form 4 |
| Jun 18, 2025 | Pimblett Emily SVP, Finance & CAO | Option | 5,000 | — | Form 4 |
| Jun 20, 2025 | Pimblett Emily SVP, Finance & CAO | Sale | 1,242 | $2K | Form 4 |
| Mar 27, 2025 | Thomas Stephen Basil Director | Option | 25,093 | — | Form 4 |
| Mar 18, 2025 | Pimblett Emily SVP, Finance & CAO | Option | 5,000 | — | Form 4 |
| Mar 20, 2025 | Pimblett Emily SVP, Finance & CAO | Sale | 1,199 | $2K | Form 4 |
| Jan 1, 2025 | Thomas Stephen Basil Director | Option | 50,188 | — | Form 4 |
| Dec 18, 2024 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Option | 5,000 | — | Form 4 |
| Dec 19, 2024 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Sale | 1,235 | $2K | Form 4 |
RA CAPITAL MANAGEMENT, L.P.
Director
Date
Jan 5
Shares
7,111
Price
$3.50
Value
$25K
RA CAPITAL MANAGEMENT, L.P.
Director
Date
Dec 12
Shares
101,462
Price
$2.86
Value
$290K
RA CAPITAL MANAGEMENT, L.P.
Director
Date
Dec 11
Shares
213,099
Price
$2.18
Value
$465K
RA CAPITAL MANAGEMENT, L.P.
Director
Date
Dec 11
Shares
20,440,000
Price
—
Value
—
Brennan Aoife
President and CEO · Director
Date
Jun 27
Shares
68,750
Price
—
Value
—
Brennan Aoife
President and CEO · Director
Date
Jun 30
Shares
20,618
Price
$1.22
Value
$25K
Pimblett Emily
CHIEF ACCOUNTING OFFICER
Date
Dec 19
Shares
1,235
Price
$2.02
Value
$2K
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About CLYM insider trading
CLYM insider trades
Climb Bio, Inc. (CLYM) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Thomas Stephen Basil (Director), RA CAPITAL MANAGEMENT, L.P. (Director), Brennan Aoife (President and CEO · Director). Over the past 12 months, 4 insiders have filed transactions with the SEC. CLYM insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Climb Bio, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
CLYM insider trading · 5 questionsThe insiders of Climb Bio, Inc. (CLYM) include executives and directors such as Thomas Stephen Basil (Director), RA CAPITAL MANAGEMENT, L.P. (Director), Brennan Aoife (President and CEO · Director), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026